Six-Month Standing Order – Quidel Ortho Reagents
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), on behalf of its Department of Transfusion Medicine, intends to award a firm-fixed-price purchase order on a sole source basis to QuidelOrtho Sales Company, LLC. This action is for a six-month standing order of QuidelOrtho reagents. This is a notice of intent, not a request for quotation. Capability statements are due by March 25, 2026, at 09:30 AM EST.
Scope of Requirement
This requirement covers a six-month standing order for specific QuidelOrtho reagents, including Anti-IgG gel cards, MTS A/B/D Mono and Reverse gel cards, Anti-IgG C3d gel cards, Surgiscreen, Affirmagen, Resolve Panel A, MTS Round Diluent 2, Alba Q-Chek controls, MTS Round Diluent 2+, BSA 7%, and MTS Buffered Gel cards. The Period of Performance is from April 1, 2026, to September 30, 2026.
Contract & Timeline
- Type: Firm-Fixed-Price Purchase Order (Sole Source)
- Duration: Six months
- Set-Aside: None (Sole Source Justification)
- Response Due: March 25, 2026, 09:30 AM EST
- Published: March 19, 2026
Justification & Authority
The sole source justification is based on the fact that QuidelOrtho reagents are the only reagents compatible with the existing Vision analyzer currently used by the department. There are no authorized distributors, and alternative products would necessitate validation, leading to delays in patient care. This acquisition is conducted under FAR Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), which permits soliciting from a single source for purchases not exceeding the simplified acquisition threshold when only one source is reasonably available. Contracts under FAR Part 13 are exempt from FAR Part 6 competition requirements.
Submission
Interested parties may submit capability statements only via email to shasheshe.goolsby@nih.gov.